1[1]Kahan B D. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters[J]. Transplantation, 1985,40(5):457-476.
2[2]Kahan B D, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy[J]. Transplantation, 1988,46(5):631-644.
3[3]Kahan B D, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic allograft rejection[J]. Transplantation, 1996,62(2):599-606.
4[4]Grevel J, Welsh M S, Kahan B D. Cyclosporine monitoring in renal transplantation:area under the curve monitoring is superior to trough-level monitoring[J]. Ther Drug Monit, 1989,11(3):246-248.
5[5]Cantarovich M, Fitchett D, Latter D A. Cyclosporine trough levels,acute rejection,and renal dysfunction after heart transplantation[J]. Transplantation, 1995,59(3):444-447.
6[6]Citterio F, Torricelli P, Serino F, et al. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation[J]. Transplant Proc, 1998,30(5):1688-1690.
7[7]Cantarovich M, Latter D, Fitchett D. Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients:a prospective randomized study[J]. Transplant Proc, 1997,29(1-2):602-604.
8[8]Johnston A. In: Rashid A ed. New strategies for therapeutic drug monitoring of Neoral. Proceedings of a meeting of the First International Advisory Board meeting[M]. Vancouver. BC. November 1997. Oxford. England,Blackwell Science Ltd, 1998.7.
9[9]Rasmussen A, Hjortrup A, Hansen B, et al. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation[J]. Transplantation, 1996,62(7):1031-1033.
10[10]Hariharan S, Johnson C P, Bresbnahan B A, et al. Improved graft survival after renal transplantation in the United States,1988 to 1996[J]. N Engl J Med, 2000,342(9):605-612.
